Acute respiratory and cardiac conditions are frequently encountered in the emergency department (ED), varying from mild to severe. Among the critically ill, up to one-third of them may have respiratory failure at presentation. Prompt and effective intervention in the ED can reduce adverse patient outcomes, decrease hospital length of stay and need for intubation, and limit resource utilization. Common conditions seen in the ED that can result in respiratory failure include acute pulmonary edema, acute exacerbation of chronic obstructive pulmonary disease (COPD), asthma, pneumonia, restrictive lung disease and bronchiectasis. Traditionally, NIPPV has been the modality of choice in management of hypercapnic respiratory failure in COPD and cardiogenic pulmonary edema. It provides positive pressure to the airways, helping to improve ventilation and reduce the work of breathing by assisting with both inspiration and expiration. It is, however, associated with side effects and complications such as pneumothorax, nasal bridge skin abrasions, claustrophobia, patient intolerance due to the positive pressure or dry and non-humidified air, gastric distension, aspiration and ill-fitting masks resulting in air leaks and eventual therapeutic failure. Additionally, patients are unable to speak or eat during application of the NIPPV mask and suctioning of oral secretions is also precluded. In the event of treatment failure with NIPPV, the next treatment modality would inadvertently be endotracheal intubation, which has its short-term risks such as peri-intubation hypotension and cardiac arrest, and longer-term risk of ventilator-associated pneumonia.
High flow nasal oxygenation (HFNO) is a relatively new modality for treating patients with respiratory failure and it involves delivering oxygen to patients using a specialized device to provide a high flow (up to 60 L/min) of warm, humidified oxygen far beyond the maximum of 4 to 6 L/min by standard nasal cannula. The benefits of HFNO include higher patient tolerance and comfort compared to NIPPV, no interruption in oxygen therapy during eating, reducing metabolic work in heating and air humidification, easy to use and monitor, and avoiding the complications associated with intubation and mechanical ventilation. Risks of skin abrasions and aspiration associated with NIPPV can also be prevented. A variety of devices exists. One variant is high velocity nasal insufflation (HVNI), which utilizes a smaller bore nasal cannula to flush airways and improve oxygenation. At the same flow rate, HVNI generates a higher nasopharyngeal pressure with a higher flow velocity than HFNO and is more effective in washing out extra-thoracic dead space,8 potentially more effective than HFNO in reducing PaCO2 levels.
The focus on HFNO has predominantly been on oxygenation rather than ventilation and the few studies on T2RF mostly focused on patients with COPD. Additionally, current evidence in HVNI use for acute hypercapnia is still lacking. Therefore, our study aims to evaluate if HVNI is non-inferior to NIPPV in reducing PaCO2 levels in acute T2RF from any cause. If proven to be non-inferior, this could be an alternative therapy for patients with respiratory acidosis, especially if they are unable to tolerate NIPPV or developed complications from it, thereby reducing the need for intubation and its potential adverse effects in such patients.
Specific aims \& hypothesis
The purpose of this study is to determine if high velocity nasal insufflation (HVNI) is comparable to non-invasive positive pressure ventilation (NIPPV) in treatment of emergency patients with acute respiratory acidosis. In our non-inferiority trial, we hypothesize that HVNI is inferior to NIPPV in reducing PaCO2 in type 2 respiratory failure (T2RF) due to any cause by a pre-specified non-inferiority margin of 4.3% decrease in PaCO2 levels after 30 minutes of treatment. Our specific aims are as follows:
1. Primary aim: To evaluate if HVNI is non-inferior to NIPPV in reducing PaCO2 levels in patients with T2RF from any cause
2. Secondary aims: To compare if HVNI is similar to NIPPV in terms of treatment failure or need for intubation, and if HVNI can improve respiratory rate and patient's comfort level, and reduce adverse events associated with NIPPV
Randomization will be performed in random permutated variable blocks of 4 and 6. The block lengths will be kept unknown to the study team as per ICH E9 guideline. However, block randomization will ensure the numbers in each group will remain similar throughout the study, should we fail to recruit the targeted number of patients. Allocation concealment will be maintained until the registration and randomization process is completed.
